Shares of Savient Pharmaceuticals Inc (SVNT) just spiked $1 in recent trade on rumors it could be the subject of a takeover.
It is not known at this point who the potential acquirer could be, but according to a Reuters article posted yesterday Abbott Laboratories (ABT), Pfizer (PFE) and Amgen (AMGN) are seen as the most likely acquirers given their existing rheumatology franchises, while Bristol-Myers Squibb (BMY), Roche and J&J (JNJ) are also potential bidders.
Shares of SVNT rose 0.96 cents, or 4.73 percent, to $21.24 in midday trading.
The East Brunswick, New Jersey-based Savient is a specialty bio company that focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the US.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply